Organization · Venture Capital
Red Tree Venture Capital
Red Tree Venture Capital is an early-stage venture capital firm based in Redwood City, California, specializing in life sciences investments, particularly in oncology, neurology, and immunology. The firm leverages strong relationships with academic institutions to source innovative companies.
Overview
What Red Tree Venture Capital does
What Red Tree Venture Capital is
Red Tree Venture Capital is an early-stage venture capital firm based in Redwood City, California, specializing in life sciences investments, particularly in oncology, neurology, and immunology. The firm leverages strong relationships with academic institutions to source innovative companies.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2020
- Approximate age
- About 6 years
- Structured capabilities
- Funder
- Last reviewed
- May 5, 2026
Official channels
Find Red Tree Venture Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Red Tree Venture Capital as a funder
Investment thesis
Red Tree Venture Capital focuses on early-stage life science companies, leveraging relationships with leading West Coast academic institutions to source transformative therapeutics in oncology, neurology, and immunology.
Focus narrative
Red Tree Venture Capital employs a West Coast-centric investment strategy, primarily targeting early-stage companies developing first-in-class and/or best-in-class therapeutics. The firm concentrates on significant unmet needs in oncology, neurology, and immunology, aiming to provide initial institutional capital to approximately half of the companies it funds.
Value beyond capital
Red Tree Venture Capital provides not only capital but also strategic guidance and access to a network of leading academic and research institutions, enhancing the growth potential of its portfolio companies.
Focus and fit
- Stages
- Seed · Series A
- Regions
- North AmericaUnited States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 10
- Recorded notable exits
- Excellergy Therapeutics, Bicara Therapeutics, Ceribell, and Cargo Therapeutics
Portfolio context
Excellergy: Focused on innovative therapeutic solutions, acquired by Novartis for up to $2 billion. Bicara Therapeutics: Engaged in developing therapies for significant medical needs, completed a $362M IPO. Rondo Therapeutics: Aims to advance drug development in its field, with a first-in-class bispecific antibody. Ceribell: Involved in innovative healthcare solutions, IPO'd in October 2024. Engrail Therapeutics: Focused on addressing large unmet patient needs, raised $157M in Series B.
Common questions
What to know about Red Tree Venture Capital
Upseed classifies Red Tree Venture Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 5, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.